Business
Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors
Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, April 27, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, April 27, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Prof. Zamir Halpern to its Scientific Board of Advisors. \n\n \n \n \n \n \n \n\n \nProf. Halpern, Senior Physician at the Gastroenterology institute in the Sourasky Medical Center in Tel-Aviv, Israel, will join the company's scientific board of advisors, moving forward with the clinical validation of the safety and efficacy of the company's novel cannabis formulations for the treatment of colon cancer.\nBased on pre-clinical trials held at the company's High Throughput Screening (HTS) facility in Israel, demonstrating positive differential necrotic effects of cannabinoids on colon cancer cells, the company continues to expand its efforts into cancers of the Gastrointestinal tract.\nProf. Halpern served as Chairman of the Israeli Association of the Study of Liver, Chairman of the Israeli Gastroenterology Association, Chairman of the National Council for Food and Agriculture and is now Chairman of the National Gastro Nutrition and Liver Diseases Council at the Ministry of Health.\nProf. Halpern joins Prof. Amos Toren on the company's scientific advisory board. \nProf. Amos Toren is the Director of Pediatric Hemato-Oncology and BMT Department at the Sheba Medical Center since 2001 and a Professor in the division of Hematology, Sackler School of Medicine Tel-Aviv University. Prof. Toren is a specialist in Pediatrics, General Hematology and Pediatric Hemato-Oncology. He also has a PhD degree in genetics and qualified as a Master of Health Administration (MHA) at the Recannati Bus...